Dimerix and its kidney drug is on track but with results of its phase III trial not due for years, a few more twists and turns are likely.

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with ...

A 65-year-old woman presents to her primary care provider with a chief complaint of "feeling winded" for the last 3 weeks.

Panelists discuss how treatment success in immunoglobulin A (IgA) nephropathy extends beyond clinical trial end points to encompass sustained proteinuria reduction, stable kidney function, symptom ...